*By Britt Terrell* Elon Musk is a man with ideas...a lot of them. But Vanity Fair's Maya Kosoff wonders if his latest project may be more than he can handle. The Tesla and SpaceX CEO won his bid to build a tunnel from downtown Chicago to O'Hare International Airport, partnering with Mayor Rahm Emanuel to modernize the city's struggling transportation system. The task, though, may be particularly tricky. "With public infrastructure, you have contracts with the government, and digging a tunnel underneath the city literally disrupts people's lives. I think it's more impactful so therefore it's kind of the most difficult (problem) to solve," Kosoff said. The issues are only exacerbated by the fact that the airport link is far from Musk's only project. His SpaceX still aims to send humans to Mars by 2014, and Tesla is developing new cars and trucks, even as it continues to struggle with meeting production targets and burns through cash. And in her article, ["Is Elon Musk Scamming Chicago?"](https://www.vanityfair.com/news/2018/06/is-elon-musk-scamming-chicago), Kosoff points out that the cost and the time it will take to construct the Chicago Express Loop may also be far higher than anticipated. "It's supposed to cost a billion dollars," Kosoff said. "But look at the cost of other public infrastructure projects in the country. It cost a billion dollars to build less than a mile of the expanded Q train on \[New York City's\] Upper East Side." Musk estimates the 18-mile track will take three years to complete and says his Boring Company - not taxpayers - will foot the bill. For the full interview, [click here](https://cheddar.com/videos/elon-musks-next-big-endeavor).

Share:
More In Business
Web3 Project Tool Thirdweb Raises $5 Million
Web3 software startup Thirdweb has raised $5 million in a funding round, coming from a group of high-profile investors, including Gary Vaynerchuk and Mark Cuban. Thirdweb says it is paving the way for the revolution surrounding the new iteration of the internet known as web3, by offering users free tools to build their own web3 projects. Thirdweb's co-founders Steven Bartlett and Furqan Rydhan join Cheddar News' Closing Bell to discuss.
Coatue and Tiger Global Purchase $100 Million Braintrust Tokens to Seed Decentralized Web3 Talent Network
Decentralized talent network Braintrust recently closed an atypical equity deal that involved investors buying $100 million in Braintrust tokens, the company's cryptocurrency. Braintrust's talent network is built on blockchain technology, which the company says allows it to be owned and built by users, instead of a centrally-controlled corporation. Braintrust users can also earn tokens for their contributions to the network and its growth. Braintrust co-founder Adam Jackson joins Cheddar News' Closing Bell to discuss.
Evaluating Blue Origin's Potential After Third Successful Manned Launch
Blue Origin launched its third manned mission over the weekend with 'Good Morning America' host Michael Strahan and Laura Shepard Churchley, daughter of astronaut Alan Shepard on board, alongside several Blue Origin investors. This comes after the spaceflight firm launched two successful missions to the edge of space earlier this year. How will these missions set up Blue Origin for success as it competes with SpaceX and other companies for space tourism domination and more? Joey Roulette, space reporter at The New York Times, joins Cheddar News' Closing Bell to discuss.
Inflation Surges Faster Than Expected to 6.8% in November
If there's any question about whether inflation is here to stay, today's November consumer price index data gives us an answer. This is the second month in a row we've seen a hot inflation reading — CPI last month rose to 6.8%, after jumping to 6.2% in October. Amid the holiday shopping season, what does this mean for consumers? And how will the Federal Reserve move forward after previously announcing it would speed up its asset taper timeline? Art Hogan, Chief Market Strategist at National Securities, joins Cheddar News' Closing Bell to discuss November's CPI jump, where consumers are hurting the most, what the Fed could do to help ease inflation, and more.
Getty Images CEO on Now Being the Right Time to Go Public
Editorial and stock photo provider Getty Images is gearing up to make its public debut via a SPAC merger with CC Neuberger Principal Holdings II bringing it to a $4.8 billion valuation. CEO Craig Peters joined Cheddar to break down the decision to go public and noted that the merger will help to pay down debt. "That's going to really enable a lot of additional free cash flow and financial flexibility into the business," he noted. "That's just going to allow us to just invest more aggressively into the business to accelerate what is already accelerating growth." Peters also discussed the legacy image platform's place going forward in the expanding world of digital assets like NFTs and the metaverse.
Coindesk Unveils List of the Most Influential People in Crypto for 2021
Ben Schiller, the managing editor for features and opinion at CoinDesk, breaks down how the year's top 10 crypto influencers were selected and what to expect from the blockchain ecosystem, especially the growth of NFTs, in 2022. "This whole crypto story has become not just a story about money or the future of money," he said. "It's also become a cultural story where it's getting into gaming, it's getting into artwork, into collectibles, and all kinds of cultural categories it wasn't in before." Schiller noted that he expects the U.S. and other world governments to establish crypto regulations in the coming year.
Astrazeneca COVID Antibody Treatment for the Immunocompromised Gets FDA Approval
Mina Makar, senior vice president of respiratory and immunology, Astrazeneca, joined Cheddar to discuss the FDA's decision to give emergency use authorization to the pharma giant's COVID-19 antibody treatment called Evusheld for immunocompromised patients For about 2 percent of the U.S. Makar noted that the injection is supposed to provide antibody protection for those who can't generate their own adequate immune response via the vaccines for a minimum of six months, though long-term trials are underway.
Load More